Zacks: Analysts Anticipate Arbutus Biopharma Co. (NASDAQ:ABUS) to Announce -$0.18 Earnings Per Share

Equities research analysts predict that Arbutus Biopharma Co. (NASDAQ:ABUS) will announce ($0.18) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharma’s earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.16). Arbutus Biopharma reported earnings per share of ($0.23) during the same quarter last year, which indicates a positive year over year growth rate of 21.7%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 3rd.

On average, analysts expect that Arbutus Biopharma will report full-year earnings of ($0.83) per share for the current financial year, with EPS estimates ranging from ($0.92) to ($0.71). For the next financial year, analysts forecast that the business will post earnings of ($0.64) per share, with EPS estimates ranging from ($0.68) to ($0.62). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.24). The firm had revenue of $3.34 million during the quarter, compared to the consensus estimate of $2.36 million. During the same quarter in the previous year, the business posted ($0.27) earnings per share.

A number of research analysts have commented on ABUS shares. HC Wainwright decreased their price objective on Arbutus Biopharma from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 8th. JMP Securities raised their price target on Arbutus Biopharma from $7.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Monday, November 8th. Chardan Capital restated a “buy” rating on shares of Arbutus Biopharma in a research report on Thursday, November 4th. Finally, Zacks Investment Research lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, November 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $6.60.

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in Arbutus Biopharma by 7.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 256,921 shares of the biopharmaceutical company’s stock worth $1,102,000 after buying an additional 16,929 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in Arbutus Biopharma during the 3rd quarter worth $626,000. BNP Paribas Arbitrage SA raised its stake in Arbutus Biopharma by 144.8% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,755 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 9,318 shares during the period. Two Sigma Investments LP raised its stake in Arbutus Biopharma by 187.7% during the 3rd quarter. Two Sigma Investments LP now owns 730,298 shares of the biopharmaceutical company’s stock worth $3,133,000 after buying an additional 476,475 shares during the period. Finally, Metropolitan Life Insurance Co NY acquired a new stake in Arbutus Biopharma during the 3rd quarter worth $98,000. 68.33% of the stock is currently owned by institutional investors and hedge funds.

ABUS traded up $0.07 during mid-day trading on Thursday, reaching $3.19. The stock had a trading volume of 720,622 shares, compared to its average volume of 2,098,755. The stock has a market capitalization of $431.51 million, a P/E ratio of -3.51 and a beta of 2.55. The firm’s fifty day simple moving average is $3.95 and its two-hundred day simple moving average is $3.35. Arbutus Biopharma has a 52 week low of $2.43 and a 52 week high of $5.87.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Further Reading: Market Capitalization in the Stock Market

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.